AN2 Therapeutics (ANTX) Interest Expenses (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Interest Expenses data on file, last reported at $7.3 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 1384.99% year-over-year to $7.3 million in Q1 2026; TTM through Mar 2026 was $7.3 million, a 1384.99% increase from a year earlier, with the FY2025 full-year figure at $170000.0, down 99.71% from the prior year.
• Interest Expenses for Q1 2026 stood at $7.3 million, up from $170000.0 in the prior quarter.
• Over the last five years, Interest Expenses for ANTX reached as high as $58.1 million in Q4 2024 and fell as low as $20000.0 in Q4 2022.
• Historically, Interest Expenses has averaged $10.6 million across 5 years, with a median of $3.3 million in 2022.
• Across the five-year window, Interest Expenses surged 208990.0% in 2023 and tumbled 99.71% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $20000.0 in 2022, then jumped by 208990.0% to $41.8 million in 2023, then surged by 38.95% to $58.1 million in 2024, then tumbled by 99.71% to $170000.0 in 2025, then surged by 4206.47% to $7.3 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $7.3 million in Q1 2026, $170000.0 in Q4 2025, and $372000.0 in Q3 2025.